Preferences help
enabled [disable] Abstract
Number of results
2009 | 56 | 4 | 717-722
Article title

Matrix metalloproteinases in serum of Emery-Dreifuss muscular dystrophy patients

Title variants
Languages of publication
In the pathogenesis of dilated cardiomyopathy (DCM) in Emery-Dreifuss muscular dystrophy (EDMD) matrix metalloproteinases (MMPs) are supposed to be involved and may have diagnostic/prognostic value. Serum levels of MT1-MMP, MMP-2 and MMP-9 were quantified by ELISA and zymography in 22 EDMD patients and 15 age-matched controls. In the autosomal-dominant EDMD MMP-2 and MT1-MMP were increased in all cases, and MMP-9 was increased in two of the eight examined patients. In the X-linked EDMD MMP-2 expression was increased in all the cases, MMP-9 level was elevated in 3 of the 14 cases, and MT1-MMP was decreased in eight of these patients. There was no evident correlation between the MMPs level and the different cardiac parameters including left-ventricular end-diastolic diameter, left atrial diameter and left ventricular ejection fraction in either form of EDMD. The presented results indicate that a changed level of matrix metalloproteinases, especially that of MMP-2 in serum, may be of value for detection of cardiac involvement in EDMD patients, especially in those patients with no evident subjective cardiac symptoms. Further follow-up studies of MMPs are needed to check if their determination is of value for monitoring of the progression of atrial/ventricular dilatation. MMPs determinations may also be useful for monitoring DCM treatment by synthetic MMPs inhibitors.
Physical description
  • Neuromuscular Unit, Institute of Clinical and Experimental Medicine, Polish Academy of Sciences, Warszawa, Poland
  • Neuromuscular Unit, Institute of Clinical and Experimental Medicine, Polish Academy of Sciences, Warszawa, Poland
  • 1st Department of Cardiology, Warsaw Medical University, Warszawa, Poland
  • Department of Respiratory Research, Institute of Clinical and Experimental Medicine, Polish Academy of Sciences, Warszawa, Poland
  • Neuromuscular Unit, Institute of Clinical and Experimental Medicine, Polish Academy of Sciences, Warszawa, Poland
  • Azeh L, Mader M, Smirnov A, Beuche W, Nau R, Weber F (1998) Experimental pneumococcal meningitis in rabbits: the increase of matrix metalloproteinase-9 in cerebrospinal fluid correlates with leucocyte invasion. Neurosci Lett 256: 127-130.
  • Banfi C, Cavalca V, Veglia F, Brioschi M, Barcella S, Mussoni L, Boccotti L, Tremoli F, Biglioli P, Agostoni P (2005) Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 26: 481-488.
  • Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Sonnenblick ED, Olivetti G, Anversa P (1995) The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 27: 291-305.
  • Blankenberg S, Rupprecht HJ, Poirier O, Bickel M, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene Investigators (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579-1585.
  • Bonnema DD, Webb CS, Pennington WR, Stroud RE, Leonardi AE, Clark LL, Mc Clure CD, Finklea L, Spinale FG, Zile MR (2007) Effects of age on plasma matrix metalloproteinase (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 13: 530-540.
  • Brilla CG, Maisch B, Zhou G, Weber KT (1995) Hormonal regulation of cardiac fibroblast function. Eur Heart J 16 (Suppl C): 45-50.
  • Buckley AE, Dean J, Mahy IR (1999) Cardiac involvement in Emery-Dreifuss muscular dystrophy: a case series. Heart 82: 105-108.
  • Fedak PW, Smookler DS, Kassiri Z, Ohno N, Leco KJ, Verma S, Mickle DA, Watson KL, Hojilla CA, Cruz W, Weisel RD, Li RK, Khokha R (2004) TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110: 2401-2409.
  • Fishbein MC, Siegel RJ, Thompson ChE, Hopkins LC (1993) Sudden death of a carrier of x-linked Emery-Dreifuss muscular dystrophy. Ann Intern Med 119: 900-905.
  • Galassi G, Modena MG, Benassi A, Nemni R, Gibertoni M, Volpi G, Colombo A (1986) Autosomal-dominant dystrophy with humeroperoneal weakness and cardiopathy: genetic variant of Emery-Dreifuss disease? Ital J Neurol Sci 7: 125-132.
  • George J, Patal S, Wexler D, Roth A, Sheps D, Keren G (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150: 484-487.
  • Goldsmith EC, Borg TK (2002) The dynamic interaction of the extracellular matrix in cardiac remodeling. J Card Fail 8 (Suppl. 6): S314-S318.
  • Kähäri VM, Saarialho-Kere U (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31: 34-45.
  • Li YY, Feldman AM, Sun Y, McTiernan CF (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98: 1728-1734.
  • Li YY, McTiernan CF, Feldman AM (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46: 214-224.
  • MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI (1990) Discoordinate expression of stromelysin, collagenase, and tissue inhibitor metalloproteinase-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumor necrosis factor-α on stromelysin expression. J Biol Chem 265: 17238-17245.
  • Marriott JB, Goldman JH, Keeling PJ, Baig MK, Dalgleish AG, McKenna WJ (1996) Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 75: 287-290.
  • Miller RG, Layzer RB, Mellenthin MA, Golabi M, Francoz RA, Mall JC (1985) Emery-Dreifuss muscular dystrophy with autosomal dominant transmission. Neurology 35: 1230-1233.
  • Munger MA, Johnson M, Amber IJ, Callahan KS, Gilbert EM (1996) Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77: 723-727.
  • Ohtsuka T, Hamada M, Saeki H, Ogimoto A, Hara Y, Shigematsu Y, Higaki J (2003) Serum levels of matrix metalloproteinases and tumor necrosis factor-α in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol 91: 1024-1027.
  • Ohtsuka T, Nishimura K, Kurata A, Kurata A, Ogimoto A, Okayama H, Higaki J (2007) Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy. J Card Fail 13: 752-758.
  • Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kűhl U, Schultheiss HP (1999) Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99: 2750-2756.
  • Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Kűry P, Strauwer BE, Schwartzkopff B (2006) Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 95: 261-269.
  • Pinelli G, Dominici P, Merlini L Di Pasquale G, Granate C, Bonfiglioli S (1987) Cardiologic evaluation in a family with Emery-Dreifuss muscular dystrophy. G Ital Cardiol 17: 589-593 (in Italian).
  • Reddy HK, Tjahja IER, Campbell SE, Janicki JS, Hayden MR, Tyagi SC (2004) Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation. Mol Cell Biochem 264: 183-191.
  • Ries C, Petrides PE (1995) Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease. Biol Chem Hoppe Seyler 376: 345-355.
  • Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, Crozatier B, Harf A, Lafuma C (1999) Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1: 337-352.
  • Rowland LP, Fetel M, Olarte M, Hays A, Singh N, Wanat FE (1979) Emery-Dreifuss muscular dystrophy. Ann Neurol 5: 111-117.
  • Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE (2002) Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4: 439-444.
  • Singer CF, Marbaix E, Kokorine I, Lemoine P, Donnez J, Eeckhout Y, Courtoy PJ (2000) The matrix metalloproteinase-1 (MMP-1) expression in the human endometrium is inversely regulated by interleukin-1 alpha and sex steroids. Ceska Gynekol 65: 211-215.
  • Spinale FG (2002) Matrix metlloproteinases. Regulation and dysregulation in the failing heart. Circ Res 90: 520-530.
  • Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallack H, Houk WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR (1999) Matrix metalloproteinase. Inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85: 364-376.
  • Spinale FG, Coker ML, Heung LJ, Bopnd BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ (2000) A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102: 1944-1949.
  • Thomas ChV, Coker BA, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97: 1708-1715.
  • Tziakas DN, Chalikias GK, Papaioakeim M, Hatzinikolau EX, Stakos DA, Tentes IK, Papanas N, Kortsaris A, Maltezos E, Hatseras DI (2005) Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 96: 1449-1451.
  • Tyagi SC, Kumar SG, Banks J, Fortson W (1995) Co-expression of tissue inhibitor and matrix metalloproteinases in myocardium. J Mol Cell Cardiol 27: 2177-2189.
  • Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ (1996) Matrix metalloproteinase activity expression in infarcted, non-infarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 155: 13-21.
  • Weber KT, Brilla CG (1991) Pathological hypertrophy and cardiac interstitium: fibrosis and rennin-angiotensin-aldosteron system. Circulation 83: 1849-1865.
  • Woessner JF (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154.
  • van Tintelen JP, Tio RA, Kerstjens-Frederikse S, van Berlo JH, Bopven LG, Suurmeijer A, White SJ, den Dunnenm JT, te Meerman GJ, Vos YJ, van der Hout AH, Osinga J, van den Berg MP, van Veldhuleen DJ, Buys CH, Hofstra RM, Pinto YM (2007) Severe myocardial fibrosis caused by a deletion of the 5' end of the lamin A/C gene. J Am Coll Cardiol 49: 2430-2439.
  • Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T (2004) Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 6: 41-45.
  • Yoshioka M, Saida K, Itagaki Y, Kamiya T (1989) Follow up study of cardiac involvement in Emery-Dreifuss muscular dystrophy. Arch Dis Child 64: 713-715.
  • Yokoseki O, Yazaki Y, Suzuki J, Imamura H, Takenaka H, Isobe M (2000) Association of matrix metalloproteinase expression and left ventricle function in idiopathic dilated cardiomyopathy. Jpn Circ J 64: 352-357.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.